Memorial Hospital Research Laboratories
The John Humm Lab
I am head of the nuclear medicine physics section, which supports research in PET/CT, targeted therapies, and molecular imaging. As both a medical and biophysicist, I investigate nuclear imaging methodologies to define tumor targets in terms of their metabolic and microenvironmental properties. I have a special interest in the quantitative imaging of tumor hypoxia — a known factor in determining resistance to treatment — and in ways of precisely delivering radiotherapy to a tumor, including targeting radionuclides using antibodies that can home in on cancer cells to provide a diagnostic image as well as deposit a therapeutic dose.
John L. Humm, PhD
Chief, Imaging and Spectroscopic Physics; Vice Chair, Research
- Medical physicist John Humm focuses on noninvasive imaging of the tumor microenvironment using nuclear imaging methods.
- Office Phone
- Loevinger-Berman Award, Society of Nuclear Medicine and Molecular Imaging (2012)
- Fellow, American Association of Physicists in Medicine (2007)
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
John L. Humm discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.